Second-Generation Antidepressants for Treating Adult Depression—An Update
Specific Comparative Harms of Second-Generation Antidepressants for Adults With MDD (1 of 3)
There is high-strength evidence that venlafaxine has a 52-percent higher incidence of nausea and vomiting than selective serotonin reuptake inhibitors as a class. Low-strength evidence suggests that when used to treat major depressive disorder (MDD), paroxetine IR (immediate release) may lead to higher rates of nausea than paroxetine CR (controlled release). The strength of evidence was high that mirtazapine is associated with more weight gain than citalopram, fluoxetine, paroxetine, and sertraline (0.8–3.0 kg after 6–8 weeks). Sertraline was associated with an 8-percent higher incidence of diarrhea than bupropion, citalopram, fluoxetine, fluvoxamine, mirtazapine, nefazodone, paroxetine, and venlafaxine at a moderate strength of evidence.
- Gartlehner G, Hansen RA, Morgan LC, et al. Second-Generation Antidepressants in the Pharmacologic Treatment of Adult Depression: An Update of the 2007 Comparative Effectiveness Review. Comparative Effectiveness Review No. 46 (Prepared by the RTI International–University of North Carolina Evidence-based Practice Center under Contract No. 290-2007-10056-I). Rockville, MD: Agency for Healthcare Research and Quality; December 2011. AHRQ Publication No. 12-EHC012-EF. Available at www.effectivehealthcare.ahrq.gov/secondgenantidep.cfm.
Your slide tray is being processed.